Benjamin Paik, Zi Heng Tee, Yoshio Masuda, Andrew Mtl Choong, Jun Jie Ng
{"title":"关于右心房旁路移植术治疗血液透析患者中心静脉闭塞症的系统性综述。","authors":"Benjamin Paik, Zi Heng Tee, Yoshio Masuda, Andrew Mtl Choong, Jun Jie Ng","doi":"10.1177/11297298221095320","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Central venous occlusive disease (CVOD) is a complication that can occur in patients with end-stage renal disease who are receiving hemodialysis. When CVOD develops, patients often require multiple re-interventions to maintain their dialysis access. CVOD can be treated by various strategies such as balloon angioplasty, stenting, lower limb or extra-anatomical grafts, hybrid grafts or surgical bypasses such as right atrial (RA). In this systematic review, we aim to evaluate the indications, technical aspects, and outcomes after RA bypass grafting for the treatment of CVOD in hemodialysis patients.</p><p><strong>Methods: </strong>A systematic and comprehensive literature search was conducted using various electronic databases. We included articles that reported described and reported outcomes of RA bypass grafting for the treatment of CVOD in hemodialysis patients. A narrative review of the indications and technical aspects of RA bypass grafting was performed. We also pooled and reported the primary patency, secondary patency, postoperative complications, and 30-day mortality of RA bypass grafting.</p><p><strong>Results: </strong>A total of 21 studies with 55 patients who underwent RA bypass grafting were included in our systematic review. Follow-up period ranged from 0.5 to 84 months. The mean pooled primary patency and secondary patency of RA bypass grafting were 8.1 ± 4.9 and 21.7 ± 20.1 months, respectively. The incidence of early postoperative complications such as surgical site infection, bleeding, and access thrombosis was 0%, 4%, and 4%, respectively. The overall 30-day mortality was 4%.</p><p><strong>Conclusions: </strong>This systematic review summarizes the patient characteristics, technical features and outcomes of RA bypass grafting in the treatment of hemodialysis-related CVOD. RA bypass grafting may be a viable last-resort option when less invasive or conventional treatment options have been exhausted.</p>","PeriodicalId":35321,"journal":{"name":"JAVA - Journal of the Association for Vascular Access","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A systematic review of right atrial bypass grafting in the management of central venous occlusive disease in patients undergoing hemodialysis.\",\"authors\":\"Benjamin Paik, Zi Heng Tee, Yoshio Masuda, Andrew Mtl Choong, Jun Jie Ng\",\"doi\":\"10.1177/11297298221095320\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Central venous occlusive disease (CVOD) is a complication that can occur in patients with end-stage renal disease who are receiving hemodialysis. When CVOD develops, patients often require multiple re-interventions to maintain their dialysis access. CVOD can be treated by various strategies such as balloon angioplasty, stenting, lower limb or extra-anatomical grafts, hybrid grafts or surgical bypasses such as right atrial (RA). In this systematic review, we aim to evaluate the indications, technical aspects, and outcomes after RA bypass grafting for the treatment of CVOD in hemodialysis patients.</p><p><strong>Methods: </strong>A systematic and comprehensive literature search was conducted using various electronic databases. We included articles that reported described and reported outcomes of RA bypass grafting for the treatment of CVOD in hemodialysis patients. A narrative review of the indications and technical aspects of RA bypass grafting was performed. We also pooled and reported the primary patency, secondary patency, postoperative complications, and 30-day mortality of RA bypass grafting.</p><p><strong>Results: </strong>A total of 21 studies with 55 patients who underwent RA bypass grafting were included in our systematic review. Follow-up period ranged from 0.5 to 84 months. The mean pooled primary patency and secondary patency of RA bypass grafting were 8.1 ± 4.9 and 21.7 ± 20.1 months, respectively. The incidence of early postoperative complications such as surgical site infection, bleeding, and access thrombosis was 0%, 4%, and 4%, respectively. The overall 30-day mortality was 4%.</p><p><strong>Conclusions: </strong>This systematic review summarizes the patient characteristics, technical features and outcomes of RA bypass grafting in the treatment of hemodialysis-related CVOD. RA bypass grafting may be a viable last-resort option when less invasive or conventional treatment options have been exhausted.</p>\",\"PeriodicalId\":35321,\"journal\":{\"name\":\"JAVA - Journal of the Association for Vascular Access\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAVA - Journal of the Association for Vascular Access\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/11297298221095320\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/5/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAVA - Journal of the Association for Vascular Access","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11297298221095320","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/5/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
导言:中心静脉闭塞症(CVOD)是接受血液透析的终末期肾病患者可能出现的一种并发症。一旦发生 CVOD,患者往往需要多次重新介入治疗,以维持透析通路。治疗 CVOD 的方法多种多样,如球囊血管成形术、支架植入术、下肢或解剖外移植物、混合移植物或外科旁路,如右心房(RA)。在这篇系统性综述中,我们旨在评估右心房旁路移植术治疗血液透析患者 CVOD 的适应症、技术方面和疗效:我们使用各种电子数据库进行了系统而全面的文献检索。方法:我们使用各种电子数据库对文献进行了系统、全面的检索,纳入了对血液透析患者进行 RA 旁路移植术治疗 CVOD 的描述和结果报告的文章。我们对 RA 旁路移植术的适应症和技术方面进行了叙述性综述。我们还汇总并报告了RA旁路移植术的一次通畅率、二次通畅率、术后并发症和30天死亡率:我们的系统性回顾共纳入了 21 项研究,55 名患者接受了 RA 搭桥术。随访时间从 0.5 个月到 84 个月不等。RA旁路移植术的一次通畅率和二次通畅率的平均值分别为(8.1±4.9)个月和(21.7±20.1)个月。术后早期并发症如手术部位感染、出血和入路血栓形成的发生率分别为0%、4%和4%。30天总死亡率为4%:本系统综述总结了治疗血液透析相关 CVOD 的 RA 旁路移植术的患者特征、技术特点和疗效。当侵入性较小的治疗方案或常规治疗方案已经用尽时,RA旁路移植术可能是一种可行的最后选择。
A systematic review of right atrial bypass grafting in the management of central venous occlusive disease in patients undergoing hemodialysis.
Introduction: Central venous occlusive disease (CVOD) is a complication that can occur in patients with end-stage renal disease who are receiving hemodialysis. When CVOD develops, patients often require multiple re-interventions to maintain their dialysis access. CVOD can be treated by various strategies such as balloon angioplasty, stenting, lower limb or extra-anatomical grafts, hybrid grafts or surgical bypasses such as right atrial (RA). In this systematic review, we aim to evaluate the indications, technical aspects, and outcomes after RA bypass grafting for the treatment of CVOD in hemodialysis patients.
Methods: A systematic and comprehensive literature search was conducted using various electronic databases. We included articles that reported described and reported outcomes of RA bypass grafting for the treatment of CVOD in hemodialysis patients. A narrative review of the indications and technical aspects of RA bypass grafting was performed. We also pooled and reported the primary patency, secondary patency, postoperative complications, and 30-day mortality of RA bypass grafting.
Results: A total of 21 studies with 55 patients who underwent RA bypass grafting were included in our systematic review. Follow-up period ranged from 0.5 to 84 months. The mean pooled primary patency and secondary patency of RA bypass grafting were 8.1 ± 4.9 and 21.7 ± 20.1 months, respectively. The incidence of early postoperative complications such as surgical site infection, bleeding, and access thrombosis was 0%, 4%, and 4%, respectively. The overall 30-day mortality was 4%.
Conclusions: This systematic review summarizes the patient characteristics, technical features and outcomes of RA bypass grafting in the treatment of hemodialysis-related CVOD. RA bypass grafting may be a viable last-resort option when less invasive or conventional treatment options have been exhausted.
期刊介绍:
The Association for Vascular Access (AVA) is an association of healthcare professionals founded in 1985 to promote the emerging vascular access specialty. Today, its multidisciplinary membership advances research, professional and public education to shape practice and enhance patient outcomes, and partners with the device manufacturing community to bring about evidence-based innovations in vascular access.